Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Myeloma represents 1.8% of all new cancer cases in the U.S. Estimated new cases in 2024: 35,780. Estimated deaths in 2024: 12,540. The 5-year relative survival…
Lilly's second in vivo cell therapy bet of 2026 signals a clear thesis: if delivering CAR constructs inside the patient works, the economics of CAR-T collapse…
Updated Phase 1 inMMyCAR data for KLN-1010 at ASCO 2026: 18 patients dosed; MRD-negative responses in all evaluable patients; 4 sCR and 2 VGPR among 6 patients…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Eli Lilly agreed to acquire Kelonia Therapeutics for up to $7B ($3.25B upfront + milestones). Gains in vivo CAR-T platform iGPS and lead candidate KLN-1010 (Phase 1 anti-BCMA for multiple myeloma). Second in vivo cell therapy bet in 2026 after the Orna deal. Expected close H2 2026. UPDATE (review 2026-06-07): Deal remains pending, expected to close H2 2026 (no closing 8-K yet). At ASCO 2026 (data released May 31, 2026) Kelonia reported updated Phase 1 inMMyCAR results for KLN-1010: 18 patients dosed, with MRD-negative responses in all evaluable patients (4 stringent complete responses and 2 VGPRs among 6 patients with >=4 months follow-up), the first patient in ongoing MRD-negative response beyond 10 months, and a manageable safety profile (all CRS Grade 1-2), materially de-risking the lead asset Lilly is acquiring.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Kelonia Therapeutics, Inc. (this deal) | 2026 | $7.0B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2026 deals · Eli Lilly and Company deals · Hematology deals